Ocular TherapeutixTM announces dosing of first patient in OTX-TKI phase 1 trial for AMD
Ocular Therapeutix™ announced the dosing of the first patient in a Phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet Age-related Macular Degeneration. The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia.
February 20, 2019